Diagnostic and prognostic biomarker test in serum and cancer tissue in pancreatic cancer
| Reference number | |
| Coordinator | RECCAN DIAGNOSTICS AB |
| Funding from Vinnova | SEK 300 000 |
| Project duration | March 2019 - December 2019 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Startups step 1 spring 2019 |
Important results from the project
The project aims to develop and validate a diagnostic blood test for pancreatic cancer as well as a tissue test that can stratify treatment and outcome. The clinical translation of the biomarker findings is enabled through large-scale clinical studies and validations.
Expected long term effects
Reccan Diagnostics has developed a serum protein panel that provides a 99.1% accuracy (AUC 0.991) for the diagnosis of pancreatic cancer. The initial findings have been made with mass spectrometry and validated by antibody-based techniques. In parallel, development of a predictive test in tumor tissue is underway, where we have identified several protein markers where expression levels have been correlated to prognosis and response to chemotherapy.
Approach and implementation
The serum panel will be incorporated in a simple and user-friendly diagnostic method platform. This method platform will be validated through multicenter collaborations within Europe and Australia based on 700 serum samples. Close collaboration between clinicians and expertise in protein research and medicine-technology enables continued business and product development and marketing.